BLS Pharmaceuticals Limited · ASX:BLS
BLS Pharmaceuticals — Bioxyne — Investor Presentation (March 2016)
29 slides from BLS Pharmaceuticals's investor presentation, March 2016
Slide 1: Bioxyne Investor Presentation
Bi xyne _ Boosting Health the Natural Way Investor Presentation March 2016
Slide 2: Forward looking statements disclaimer
This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Bioxyne Limited (Bioxyne) can give no assurance that these expectations will prove to be corr
Slide 3: Bioxyne
Bioxyne Product development company based on proprietary strain of probiotic Lactobacillus fermentumNRI\-003 (“PCC®”) Significant scientific and clinical data supports the marketing of the probiotic PCC® is currently manufactured in Denmark and PCC®-based products are sold in the US, Europe and part
Slide 4: What are probiotics?
What are probiotics? allb allb allb Natural micro-organisms which provide a beneficial health effect by aiding digestion and/or by triggering the immune system Probiotic products may contain a single strain or many strains, and the number of organisms in a daily dose can range from 1 billion to more
Slide 5: Probiotic industry - Growth opportunities
Probiotic industry - Growth opportunities Probiotic Ingredients Market Size, by Region, 2015 vs 2020 (USD Million) allb The probiotic ingredients market is estimated to be valued at US$33 billion in 2015 7) = Itis projected to reach US$47 billion by 2020 33) mRoW @Asia-Pacific This represents a CAGR
Slide 6: Probiotic supplement growth by country
Probiotic supplement growth by country South Korea -24% Japan 1% Poland 2% Italy 3% Germany 7% France 9% Mexico 11% UK 14% Russia 16% USA 18% Spain 24% Canada 29% Brazil 46% China 105% -40% -20% 0% 20% 40% 60% 80% 100% 120%
Slide 7: PCC® is Bioxyne's patented probiotic strain
PCC® is Bioxyne’s patented probiotic strain Lactobacillus fermentum VRI-003
Slide 8: PCC® features and benefits
PCC® features and benefits a Stable at room temperature Refrigeration not required to maintain biological activity Resistant to bile acids, pepsin, & Can be supplied in standard low pH capsules or as a powder Adheres to Gl tract Long-lasting effects Ability to colonise GI tract Human origin Adapted
Slide 9: 1 Cox et al. 2008; West et al. 2011 2 French and Penny 2009
1 Cox et al. 2008; West et al. 2011 2 French and Penny 2009 3 Weston et al. 2005
Slide 10: PCC® is safe
PCC® is safe ({l) ({l) ({l) ({l) ({l) Used since 2002, with no reported consumer adverse effects Tested in clinical studies in doses up to 12 billion CFU/day, with no reported serious adverse events The USFDA has granted Lactobacillus and Bifidobacteria “generally regarded as safe” (GRAS) status Lac
Slide 11: Bioxyne wholesales PCC® globally
Bioxyne wholesales PCC® globally a - fatfense Seater Une estan ——— lancer Enterog gratis. S eA Adel PCC® is the active ingredient in existing products distributed (lb globally Active ingredient manufactured Cieeee by industry leader Products manufactured and PUREO PHARMA «lb a SYNBIOTICS distributed
Slide 12: Chr Hansen - Manufacturer AND customer
Chr Hansen - Manufacturer AND customer | CHR,HANSEN | Proven world class GMP production capability mmproving food. & health Trusted global supplier of lactic acid bacteria for more than a century allb Bioxyne’s strategic relationship provides access to: = Certified and authorized production sites in
Slide 13: Chr Hansen - Manufacturer AND customer contd
Chr Hansen - Manufacturer AND customer contd Chr Hansen is a growing distributor of products using PCC - Bioxyne receives a royalty from these sales allb Both Bioxyne and Chr Hansen are committed to maintaining a close and continuing supply arrangement with competitive pricing and high quality produ
Slide 14: Nu-Skin - Key customer
Nu-Skin - Key customer allb allb Nu-Skin Enterprises (VYSENUS)is a US-based direct selling and multilevel marketing business Develops and distributes anti-aging personal care products and dietary supplements Nu-Skin’s products are marketed through the Pharmanex brand mH)! ProBio™ LIVE PROBI Maiatain
Slide 15: Probiotic product market segments
Probiotic product market segments 6.0% 10.0% Functional foods Dietary supplements Animal feed 84.0% While all segments are expected to grow over the coming years, industry commentary tends to emphasis growth within the animal feed market.
Slide 16: Subject to appropriate regulatory and manufacturing considerations
*Subject to appropriate regulatory and manufacturing considerations being satisfied
Slide 17: Functional food opportunities
Functional food opportunities = Potential PCC-based food products = Infant formula = Margarine / spreads = Health food bars = Chocolates = Fermented drinks = Yoghurt = Oils
Slide 18: Potential new clinical studies using PCC®
Potential new clinical studies using PCC® = Gastrointestinal health in healthy population - microbiome shift after sustained dosing = Effect on vaginal candidiasis = Effect on weight loss = Effect on mood
Slide 19: Patent portfolio: Probiotic Bacterium Lactobacillus fermentum
Title Territory Patent no. Status Priority Date Australia 2003245473 Granted 17-Feb-03 Australia 2003258366 Granted 08-Sep-03 Brazil Pending 06-Sep-02 Canada 2497989 Granted 08-Sep-02 Probiotic Bacterium Lactobacillus China ZL03823833.0 Granted 08-Sep-02 fermentum Europe 1539927 Granted 08-Sep-02 Ja
Slide 20: Gross Profit and Net Profit/(Loss)
1/7/15 - FY13 FY14 FY15 29/2/16 Revenue $880,497 $2,304,921 $1,492,701 $1,468,329 Gross Profit $478,329 $1,063,696 $926,690 $847,651 Net Profit/(Loss) ($221,671) $169,015 $201,039 $417,550
Slide 21: Balance Sheet, Cash and Equity Reserves
Balance Sheet, Cash and Equity Reserves ({l) ASX Listed - (ASX -BXN) ({l) Current (March 2016) cash reserves > $1.4m Balance sheet values strategic investment in Mariposa Health Inc. ({l) at cost ($325,000) - current indicators of potential listing price value this at > $900,000; = 200,343,101 share
Slide 22: 2016/2017 targeted clinical studies to refresh PCC® presence and data
2017/2018 – Exploitation of other 2017 –launch PCC®-based opportunities - products into China and functional foods and wider Asia veterinary potential Undertake further clinical Undertake further 2016/2017 – targeted clinical studies targeted studies targeted at clinical studies to refresh at custom
Slide 23: Resource and organisational infrastructure to grow the business
1 Jan 2016 Resource Hire people andand Hire people obtain obtainorganisational infracturetotogrow organisational infrastructure grow thethe business business We are Here Protect the current Proactively reinforce key customer and supplier relationships business Grow the Develop new distributor and cu
Slide 24: Resource and consolidate
Resource and consolidate 1 Jan 2016 Appoint BDM with scientific and industry expertise Grow relationships with key customers and suppliers We are Here Launch new products in Australia Commence process for PCC® sales in China Consolidate and build Understand customer needs for product performance Des
Slide 25: Years 2-5: Growth through sales and product acquisition
Years 2-5 Growth through sales and product acquisition 1 Oct 2016 Develop relationships with new probiotic distributors Develop relationships with new probiotic customers Enhance the Bioxyne product line Expand to new products/segments/geographies 1 Jan 2021
Slide 26: Bioxyne Limited - People
Bioxyne Limited - People = Non-Executive = Executive Team = Mr Tony Ho (Chairman) = Dr Peter French (Executive Director) = Mr Patrick Ford (Director) = Mr Jarrod White (CFO and Co Sec) = Mr George Cameron-Dow = Mr Ashok Jairath (Gales Manager) (Director) Sydney and Perth presence Low overhead struct
Slide 27: Top Holders Snapshot
Top Holders Snapshot - Grouped Composition : ORD Rank Name Units % of Units 1. ONDEK PTY LTD 39,868,277 19.90 2. WIGRAM TRADING PTY LIMITED 17,457,671 8.71 3. PT SOHO INDUSTRI PHARMASI 9,678,085 4.83 4. PROF ROBERT LLEWLLYN CLANCY + MRS CHRISTINE MARY CLANCY <CLANCY SUPER FUND NO 2 A/C> 9,564,390 4.
Slide 28: Share price - Year performance
Share price - 2 Year performance BXN - Monthly Line Chart [Clase] BXN - Volume (with MA) [200] apIM Doro 15 Joel 10 15 FIM api Doro 5 foain 10 [16 [March
Slide 29: Boosting Health the Natural Way
Boosting Health the Natural Way